Physician profile
Challa Ajit
NPI 1598778805
$12,137.09
in general payments reported to CMS, 2019-2025
41 companies · $2,617 in 2025
The $2,617 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $923 · 2021: $1,431 · 2022: $1,438 · 2023: $1,862 · 2024: $2,494 · 2025: $2,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,763 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,762.83 |
| Education | $210.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,655.72 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,309.02 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,034.23 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $984.96 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $745.45 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $568.16 | 2019-2025 | Livdelzi |
| Merck Sharp & Dohme LLC | $409.31 | 2019-2024 | Dificid |
| Pfizer INC. | $389.35 | 2019-2025 | |
| Celgene Corporation | $294.12 | 2021-2023 | Zeposia |
| Genzyme Corporation | $288.53 | 2022-2025 | |
| Ardelyx, INC. | $266.59 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $239.59 | 2020-2024 | Linzess |
| Allergan, INC. | $196.51 | 2019-2020 | |
| Daiichi Sankyo INC. | $148.72 | 2019-2022 | |
| Shionogi INC | $133.85 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $123.06 | 2023 | |
| Organon LLC | $115.25 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Lilly USA, LLC | $114.94 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $108.76 | 2019-2022 | |
| Redhill Biopharma INC. | $99.17 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Phathom Pharmaceuticals, INC. | $96.53 | 2024 | Voquezna |
| Amag Pharmaceuticals, INC. | $89.41 | 2019-2022 | |
| Novo Nordisk INC | $81.80 | 2023-2025 | Wegovy |
| Celltrion USA INC. | $77.64 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $60.89 | 2019-2025 | Rebyota |
| Evoke Pharma, INC. | $57.09 | 2024-2025 | |
| Amgen INC. | $54.08 | 2021-2025 | Uplizna |
| Regeneron Healthcare Solutions, INC. | $48.39 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $48.07 | 2024-2025 | Vowst, Zenpep |
| Ipsen Biopharmaceuticals, INC | $44.83 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $38.11 | 2021 | |
| Romark Laboratories, Lc | $36.52 | 2019 | |
| Capsovision, INC. | $33.32 | 2023-2025 | Capsocam Plus |
| Alfasigma USA, INC. | $32.59 | 2020-2022 | |
| Medtronic, INC. | $19.65 | 2025 | Interstim |
| Alnylam Pharmaceuticals INC. | $18.22 | 2021 | |
| Shire North American Group INC | $17.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.90 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $14.72 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $13.74 | 2019 | |
| Lucid Diagnostics INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Challa Ajit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.